PriceTargets.com logo

NASDAQ:NVCN - Neovasc Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 165.60 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.75 As of 09/17/2021 05:00 PM ET
▼ -0.02 (-2.59%)

This chart shows the closing price for NVCN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neovasc Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCN

Analyst Price Target is $2.00
▲ +165.60% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Neovasc in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 165.60% upside from the last price of $0.75.

This chart shows the closing price for NVCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Neovasc.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2021SVB LeerinkReiterated RatingBuy$2.00High
11/6/2020SVB LeerinkLower Price TargetOutperform$6.00 ➝ $2.00High
8/20/2020SVB LeerinkReiterated RatingOutperform ➝ Market Perform$6.00High
7/2/2020HC WainwrightReiterated RatingBuy$5.00N/A
5/8/2020HC WainwrightReiterated RatingBuy$9.00 ➝ $5.00Medium
4/14/2020Noble FinancialInitiated CoverageOutperform$15.00High
3/31/2020Canaccord GenuityLower Price TargetBuy$5.00 ➝ $3.00Medium
11/4/2019HC WainwrightSet Price TargetBuy$9.00Medium
10/24/2019HC WainwrightInitiated CoverageBuy$9.00High
3/29/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$10,500.00 ➝ $5,000.00Low
3/29/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$50,000.00 ➝ $20,000.00High
1/19/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$10,500.00High
4/5/2017LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$40,000.00High
4/3/2017JMP SecuritiesReiterated RatingOutperform$50,000.00Medium
3/23/2017SVB LeerinkReiterated RatingOutperformHigh
12/27/2016SVB LeerinkReiterated RatingOutperform$100,000.00N/A
12/7/2016LADENBURG THALM/SH SHReiterated RatingNeutralN/A
12/6/2016SVB LeerinkReiterated RatingOutperform$100,000.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/21/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2021

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Neovasc logo
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
Read More

Today's Range

Now: $0.75
Low: $0.74
High: $0.78

50 Day Range

MA: $0.80
Low: $0.74
High: $0.90

52 Week Range

Now: $0.75
Low: $0.68
High: $2.66

Volume

657,611 shs

Average Volume

2,645,511 shs

Market Capitalization

$50.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Neovasc?

The following sell-side analysts have issued reports on Neovasc in the last year: SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for NVCN.

What is the current price target for Neovasc?

1 Wall Street analysts have set twelve-month price targets for Neovasc in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 165.6%. SVB Leerink LLC has the highest price target set, predicting NVCN will reach $2.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $2.00 for Neovasc in the next year.
View the latest price targets for NVCN.

What is the current consensus analyst rating for Neovasc?

Neovasc currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVCN will outperform the market and that investors should add to their positions of Neovasc.
View the latest ratings for NVCN.

What other companies compete with Neovasc?

Other companies that are similar to Neovasc include TELA Bio, Titan Medical, Neuronetics, T2 Biosystems, Nemaura Medical, Liquidia, BrainsWay, PolyPid, Repro Med Systems, Venus Concept, AIT Therapeutics, Repro-Med Systems, Lyra Therapeutics, Isoray and Pro-Dex.

How do I contact Neovasc's investor relations team?

Neovasc's physical mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider's listed phone number is (604) 270-4344 and its investor relations email address is [email protected] The official website for Neovasc is www.neovasc.com.